Loading stock data…
$2.46-0.06 (-2.38%)
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
Kiora Pharmaceuticals, Inc. in the Healthcare sector is trading at $2.46 with a market capitalization of $12M. Wall Street consensus targets $12.00 (1 analysts), implying a +387.8% move over the next 12 months. The stock is currently 15% below its 52-week high of $2.91, remaining 2.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.12M↑ | -$2.50M↑ | -$2.63M↓ | -$2.52M↓ | -$2.26M |
| Net Income | -$2.08M↑ | -$2.42M↑ | -$6.52M↓ | $26,806↑ | -$2.15M |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small mo...